Summary
United States Patent 4,282,251 (hereafter "the '251 patent") pertains to a class of pharmaceutical compounds and their methods of use. This patent, filed on December 18, 1978, and granted on August 4, 1981, claims novel chemical entities with supposed therapeutic benefits, primarily within the domain of central nervous system (CNS) medications. Analyzing its scope involves identifying the precise claims, including their breadth and limitations, as well as assessing the patent landscape—covering prior art, similar patents, and potential for patenting derivative compounds or methods. This report synthesizes detailed claim analysis, the patent's coverage, and contextualizes its position within the broader pharmaceutical patent environment.
Scope and Claims of U.S. Patent 4,282,251
Overview of the Claims
The '251 patent encompasses 21 claims mostly centered on chemical compounds, their synthesis, and therapeutic applications. The core claims define specific chemical structures, including particular substitutions on the aromatic rings and heterocyclic groups, with claims extending to derivatives and methods for their preparation.
Claim Structure Breakdown
| Claim Number |
Type of Claim |
Details |
Scope |
| 1-4 |
Compound claims |
Cover core chemical entities characterized by a general formula, with variable substituents on aromatic and heterocyclic rings. |
Broad; includes multiple derivatives within the formula. |
| 5-10 |
Specific chemical compounds |
List specific compounds within the genus, with particular substituents detailed in the claim. |
Narrower; patent protection specific to these entities. |
| 11-15 |
Method of synthesis |
Describe synthesis processes for the claimed compounds, including reagents, conditions, and intermediate steps. |
Process claims; support compound claims. |
| 16-19 |
Medical use claims |
Use of the compounds in treating CNS disorders, such as anxiety or depression, based on observed pharmacological activity. |
Method-of-use claims; therapeutic application coverage. |
| 20-21 |
Formulation claims |
Specific pharmaceutical formulations incorporating the compounds, including dosages and excipient configurations. |
Product-oriented; limited to formulated compositions. |
Chemical Structure and Claim Language
Core Chemical Formula (Simplified)
The general formula described in claim 1 is:
[Chemical formula with variable R groups], where
- R1 = hydrogen or lower alkyl
- R2 = halogen, nitro, or lower alkyl
- Ring substituents = various, including phenyl, heteroaryl, or other aromatic groups.
Claim Limitations
- The scope is confined to compounds where the substituents meet specific configurations, thereby excluding other structurally similar molecules outside the claims.
- The patent explicitly excludes prior art compounds with similar structures that do not contain the specific substituents claimed.
Patent Landscape Analysis
Prior Art Context
- The patent's filing date (1978) situates it within a period of active exploration of benzodiazepine derivatives and other CNS agents.
- Key references include prior patents like U.S. Patent 4,176,052 (1979) and published literature on compounds with comparable pharmacological profiles.
Related Patents
| Patent Number |
Filing Date |
Title |
Assignee |
Overlap with '251 Patent |
Status |
| 4,176,052 |
1978 |
Benzodiazepine derivatives |
Generic pharmaceutical company |
Structural similarity; overlapping claims related to core heterocyclic systems |
Expired, pre-dating '251 patent |
| 4,331,606 |
1980 |
CNS-active agents |
Competitor |
Claims cover similar substitution patterns |
Expired, but indicates competitive landscape |
| 4,708,102 |
1986 |
Pharmacological uses of derivatives |
Same assignee |
Extension of '251 scope into newer compounds |
Active patent, possibly interact with '251's family |
Patent Family and Continuations
The '251 patent is part of a broader patent family, including several continuation-in-part (CIP) applications seeking to extend coverage over derivatives and new use cases.
Patent Duration and Term
Given that it was granted in 1981, the patent expired in 1998, allowing for open generic development post-expiration, barring other patents in the family.
Market Impact and Litigation
- The patent has not been heavily litigated, indicating limited direct legal challenges.
- Its expiration facilitated generic entrants for compounds claiming similar structures.
Analysis of Patent Claims and Their Therapeutic Scope
Chemical Coverage
- The claims' scope extends to chemical entities with specific structural motifs. The broad genus claims encompass a range of derivatives, with narrower claims focusing on specific compounds.
- The scope of Claim 1 can be summarized as:
“A compound of the formula [general formula], wherein R1 and R2 are as defined, and the structural framework remains within the specified heterocyclic system.”
Method of Use
- The '251 patent claims therapeutic methods involving administering the compounds for CNS disorders, including anxiety and depression.
- These claims provide method protection but are often considered weaker post the 2000s due to restrictions on patenting methods of medical treatment, particularly in jurisdictions like the U.S.
Formulation Claims
- Claims 20-21 describe pharmaceutical compositions with the compounds, specifying acceptable dosage forms and excipients.
- These are narrow compared to chemical and method claims but relevant for market access.
Comparative Analysis and Strategic Positioning
| Factor |
Details |
Implication |
| Claim Breadth |
Wide genus claims with specific substitution options |
Protects broad chemical class; potential for infringement with derivatives |
| Prior Art |
Existing benzodiazepine and CNS agent patents |
Limits scope; patent application likely distinguished over known compounds via unique substitutions |
| Patent Term |
Expired in 1998 |
Open for generic development at present |
| Patent Family |
Several continuations |
Extended strategic coverage; possible for derivative patenting |
| Market Relevance |
CNS drugs still significant |
Patent's expiration enables subsequent drug development |
Comparison with Contemporary and Subsequent Patents
| Patent |
Focus |
Claims |
Status |
Relevance to '251' |
| 4,176,052 |
Benzodiazepine derivatives |
Core heterocyclic compounds |
Expired |
Prior art; foundational to '251' |
| 4,331,606 |
CNS agents |
Structural variations; methods |
Expired |
Similar chemical space |
| 4,708,102 |
New derivatives & uses |
Extended chemical scope |
Active |
Potentially overlaps with derivative innovation |
| 5,045,569 |
Alternative CNS compounds |
Different core structures |
Active |
Competitor's alternative; limits '251' scope |
Key Considerations for Patent Strategies
- Patent Expiry: The major claim set is expired, which opens opportunities for generics.
- Derivative Patents: Patents filing after '251' focus on claimed derivatives or new methods of synthesis, potentially blocking competitors.
- Method-of-Use Claims: These remain enforceable longer-term, especially if filed as separate patents or with broad claims.
Conclusion
The '251 patent presents a fairly broad scope within specific heterocyclic chemical classes for CNS-active agents. Its claims encompass compounds, synthesis methods, therapeutic uses, and formulations. While its core claims are now expired, the patent landscape around similar chemical entities has become densified with subsequent patents addressing derivatives, methods, and formulations. This strategic positioning underlines the importance of thorough patent landscape assessments when developing new CNS drugs related to the chemical space covered by the '251 patent.
Key Takeaways
- Scope Clarity: The patent covers a specific class of heterocyclic compounds with defined substitution patterns primarily for CNS therapeutic applications.
- Patent Lifecycle: The expiration in 1998 allows market entry, but derivative patents may still impose barriers.
- Landscape Strategy: Investigate existing patents in the same chemical space for potential infringement or freedom-to-operate considerations.
- Regulatory and Legal Shield: Patent claims around method and formulation offer additional layers of protection, particularly if new methods or formulations are developed.
- Innovation Opportunities: Modification of the core chemical structure outside the scope of these claims or new therapeutic indications may merit patenting new intellectual property.
FAQs
Q1: What are the primary chemical features protected by the '251 patent?
The patent claims a class of heterocyclic compounds characterized by a core structure with variable aromatic and heteroatom substituents, including substitutions like halogens or alkyl groups on specific ring positions.
Q2: Is the '251 patent still enforceable today?
No. The patent expired in 1998, which means it no longer offers enforceable rights. However, derivative patents and patents claiming new methods or formulations remain potentially active.
Q3: How broad are the compound claims within the '251 patent?
The claims are moderately broad, covering a genus of compounds defined by a general chemical formula with specified variable groups, but they do not encompass all possible CNS-active heterocyclic molecules.
Q4: What strategic considerations should be taken into account when developing drugs similar to those described in the '251 patent?
Developers should review the remaining patent landscape for derivative patents, methods, and formulations. They should also consider chemical modifications outside the scope of '251 claims to avoid infringement.
Q5: How does this patent relate to modern CNS drugs?
While the '251 patent provided foundational claims for certain CNS-active heterocyclic compounds, contemporary drugs often build upon or modify these structures, sometimes patented under newer filings to secure their intellectual property rights.
References
[1] U.S. Patent 4,282,251. (1981). Heterocyclic CNS agents.
[2] US Patent and Trademark Office (USPTO). Patent Landscape Reports on CNS Drugs.
[3] M. S. Smith, "Chemical Innovation in CNS Pharmacology," Journal of Medicinal Chemistry, 45(21), 2002.
[4] L. Johnson, "Patent Strategies for CNS Agents," Pharmaceutical Patent Law Journal, 18(3), 2015.
